Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval for a clinical trial of their innovative drug, SKB500, aimed at treating advanced solid tumors. This novel ADC drug, developed using the OptiDC platform, has shown promising preclinical results. Investors are advised to exercise caution as the drug’s development and commercialization are not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.